ReViral
ReViral is a UK-based biotechnology company with a portfolio of drugs to treat Respiratory Syncytial Virus (RSV) infection. RSV currently represents a major unmet medical need in children, the elderly and the immuno compromised.
Our most advanced programme, RV521, is a highly potent, orally-administered inhibitor of RSV fusion protein, and has demonstrated top-line safety and pharmacokinetic data in Phase1 single and multiple ascending dose (SAD and MAD) trials. RV521 has successfully completed a Phase 2a proof-of-concept study in adult volunteers. RV521 will start clinical trials in patients in 2018.
Follow @ReViral_ltd
Fascinating #washingtonpost article on the effect of #COVID19 lockdowns on other common viruses, including #RSV. And the possibility of a strong rebound of these viruses in the not-too-distant future.... washingtonpost.com/health/2021/01…
See other Therapeutics organisations
-
AKL Research & Development Ltd.'s focus is in inflammatory diseases, particularly those related to dysregulation of the innate immune system. -
Antabio is a private biopharmaceutical company developing a broad pipeline of novel antibacterial treatments focused on drug-resistant life threatening infections. ... -
To 2014 - Antikor Biopharma Limited was established in mid-2014 following the restructuring of PhotoBiotics Limited. The new Company retains ... -
Apollo Therapeutics is a collaborative venture between three world-leading UK universities (Imperial College London, University College London and the University ...
Stevenage Bioscience Catalyst is the UK's leading open innovation campus with a focus on therapeutics.
Learn moreCopyright © 2021 Stevenage Bioscience Catalyst
We use cookies to improve our site experience. Press accept to agree to our Cookie Policy. If you decline, your information won’t be tracked when you visit this website. A single cookie will be used in your browser to remember your preference not to be tracked.